NCT02965924|CompletedResults
Loading search results
Sponsor study identifier
interventional
20
1 country
1
Study Start
October 2016
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
October 1, 2018
Actual (reported)Study Completion
October 1, 2018
Actual (reported)Phenylephrine hydrochloride ophthalmic solution is an alpha-1 adrenergic receptor agonist commonly used topically for dilation prior to ocular fundus examination. In the eye, phenylephrine acts locally as a potent vasoconstrictor and mydriatic by constricting ophthalmic blood vessels and the radial dilator muscle of the iris. Episcleral venous pressure (EVP) is a determinant of intraocular pressure (IOP) and can be measured non-invasively by venomanometry. Since phenylephrine is a vasoconstrictor, it may affect episcleral venous tone, but the effect on EVP is unknown. Understanding the physiology of episcleral veins helps us in better understanding of pathophysiology of glaucoma.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 1, 2018
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 2016
Date type not reportedThis date has not been verified as actual or estimated.
November 15, 2016
Actual (reported)November 17, 2016
Actual (reported)October 1, 2018
Actual (reported)October 1, 2018
Actual (reported)October 23, 2019
Actual (reported)Change in Episcleral Venous Pressure (EVP)
EVP will be measured non-invasively using a custom-modified slit-lamp mounted venomanometer. This device utilizes the pressure chamber technique, in which a clear flexible balloon is placed against the conjunctival surface of the eye, and the pressure is increased until an episcleral vein is noted to blanch. The system for pressure-chamber based venomanometry includes a computer-controlled motor drive to increase pressure automatically, a transducer to record pressure, and a high-definition video camera to record vein collapse. Pressure measurements are synchronized with the video stream and image analysis software is used to determine the pressure required to collapse the vein to a specific pre-determined degree as measured in mmHg.
baseline, 60 minutes
Change in Intraocular Pressure (IOP)
baseline, 60 minutes
Subjects will receive topical phenylephrine 2.5% eye drop instilled in one eye after all baseline measurements.
Instilling phenylephrine 2.5% eye drop
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Arthur J Sit, M.D.
Mayo Clinic
20 participants (actual enrollment reported by the registry).
First Submitted
November 15, 2016
First Posted
November 17, 2016
Study Start
October 2016
Date type not reportedThis date has not been verified as actual or estimated.
Detecting Hypotension By Continuous Non-invasive Arterial Pressure Monitoring
Contact the study team to confirm eligibility.
Primary Completion
October 1, 2018
Actual (reported)Study Completion
October 1, 2018
Actual (reported)Last Updated
October 23, 2019
Results First Posted
October 23, 2019
Record last verified: 2019-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: